# FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

> **Open Intelligence Dossier** · First detected: 2026-07-28 00:07 UTC · Category: Business

## Executive Summary
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’" is generating significant coverage in the Business category, with 10 articles from 9 distinct sources tracked by PULSE so far.


Outlets currently covering the story include BioWorld News, Managed Healthcare Executive, Medscape and MedPage Today. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioWorld News | Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxNWWc2SkVIclBvdlN4dmN2cnJXRHBrdmhKOU1qb1Y5Zmk1UE10Q1I1b3lJaDlPNTNrQXI0U1VNR2wxem4wMVRaVkExdHZTNWRzZTlnaU5teE94eVJLRkZzZXpfN1hneXZOWnJVXy1OaHptZnYyc08xSGFEa2xIN3FPZUJxWmdKdkFxeDdlbGMzaw?oc=5) |
| Managed Healthcare Executive | FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxPUXhBTU5vbkFDWUVnS1B6dFM0ai03WVN3TXc1VFctTEtPNjcxUHdDaWktbnNtT0hPUFJDT0lkb194QnhOSmlZRlVQY3hEcHdQT0haZ1pVZHhDMnl3WmNneEt0cV9GWlVGM3YxMmw2bmxpeXNKS0wzb3ZEQUZCazkzRW9zLVpnbC1HcE9wQTNiUDNnZ3cwc25oaXNrVFRxb04xUHNIQU9SUXVxS0RRNmFsNWNReWE?oc=5) |
| Medscape | FDA Approves First NDSRI for ADHD in Adults and Children | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxQdmFVTXJvZFRVZlNPM3dldWdMV0gxUzBqbXNYa1F6d1pCR1ViclJEWEdXWHdfWUJicHBYQVZ0RUg2Z2piZU8xRXRaUWJLY3JDNDhoZXBiaTNrWEptZGwxellrelZ5b3VWR0FnRVhwUVJBSlNhR01xNUtoVGNmdk9sYno1RjBtTEVxR0VEWE5va1FRN2hxaDIwWXdWTUZnZVZk?oc=5) |
| MedPage Today | First-in-Class Drug for ADHD Wins FDA Approval | [Source Link](https://news.google.com/rss/articles/CBMiZkFVX3lxTE1Td3hfMF9hN1haY3daczdUcVBYM1J0YmFwWUpSMEo2bGJTcUNFVGZ5ZXF0X19nZ3hQeFZaOFhqZkNhTTFtakRsVk5fRjZlUWNtUExnV3pjdjVPQWFPQjd3Z3p3MURNUQ?oc=5) |
| BioWorld News | Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxNTmZYb1IzRW9SX3N6M2Q1WkhJaGk0bFBWUzhUZkhoaksyaVhrUFA1eXVRVXNzMG9nYjBZWDN1TmVsNTlsZjR0Y2FSSkYxdy1mTVJMQm1oWjQwdEhvaGY3UF9GOWRuQm96ZXhCSTNUMkw4M1VfSk9LMEtsYlE0X3lsZFZfbVgxR3VvU0hnRlBCQQ?oc=5) |
| Pharmaceutical Executive | FDA Approves Simtriyo - PharmExec | [Source Link](https://news.google.com/rss/articles/CBMiakFVX3lxTE5vTng0c090SFFjNjVWRnAzMWJpRlpXTy05dFRhRDZvR1hHZUFSdXlLRGpQcTh1MnVkeVhtUzlQaHFfZWxFN1VlMFAzaHg2N1piYThNZHEzU1pMWXdyNzVFWkpjNnltQWkxbmc?oc=5) |
| FirstWord Pharma | Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE1rTTIwMldNUl9jLWpQdzJVcV9xcjN1NWZ2SExRMmR3RkRKdlB6X0RjbWxfbVZjSlNmUmpVUFB5ekFUV2lEa0xJQlFXNzVSd1lOQWdV?oc=5) |
| BioSpace | Otsuka’s ADHD approval opens up new drug class with $615M opportunity | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxNNkhDWkRCeFJfS3FPeDdlV0pMQXg2ekdLX0RDN1NST2x2dlFOWXBReGJ4MXJ3VTV0WmMwczdNQjJDQVpyUDlXSjJ0bUlBbmNteU1VdWZRNGpjdzB0a1hCNWE5dzNxNlJwclJNMmxTTUJZOEQ5UmZnZnRRTEF5dnExT3VjbFU2RmtKVkpwVElNd3JRWnpsQzBKVUJoUE0?oc=5) |
| Psychiatric Times | FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxNWVpXRXJiNWVVbkt2TlhESndrV1FQUi1abjJqejNxb0pDR2ZWVDNWZElZN1hUb2dCZlU5WkFMSGF0Q1ZLZURGdjhpQzc1cEQ3d2tRa0EzbzcxRl9keWxhb1E4cGl5eFVRY2V5VXI3Z3FzQm9OdTJrSUdzRE5hUUlOSl80WXdIRVMteGtnalB5OUFDVGxLSFpXQkxQajhhV3VvRGk0LXBlNTNHdllT?oc=5) |
| Fierce Pharma | FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZGVESENwUnNpRjRFOGZ1czkybW9IR0d2RzFZLWF0OFdBMDRKMU01Z2hXTlRKclZ1UHZhR2lBc2RtUTF5NEdweFltdGtPT0RMZEF3Yi1yM3JfZ3RsX1VhaEkxTEdYdW9wVUJ2WFlVUEd4eXN4UTQ4akJUaGNMUEM4WWxRblVfNnJqLXJndlhQbkJmNk42U3ZiNDUtMUFvMEd2SUJ0akFfc1pNc00?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-28/fda-approves-otsuka-s-adhd-drug-simtriyo-teeing-up-its-next-major-cns-launch*